Central Trust Company’s Astera Labs ALAB Stock Holding History

Central Trust Company’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$220	–	1689
2026 Q1	$220	Sell	2 -2	-50%	-$285	﹤0.01%	1541
2025 Q4	$676	Buy	+4	New	+$669	﹤0.01%	1410

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Central Trust Company's ALAB Position: Q2 2026 in Review

Central Trust Company sold out of Astera Labs (ALAB) in Q2 2026, closing a stake of 2 shares — an estimated $220 sold.

Central Trust Company first reported a position in ALAB in Q4 2025 and held it in 2 quarters. The position peaked at $676 in Q4 2025. 988 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

Central Trust Company reported no remaining Astera Labs position as of Q2 2026 after selling out during the quarter.
Central Trust Company sold 2 Astera Labs shares in Q2 2026, an estimated $220.
Central Trust Company first reported a position in Astera Labs in Q4 2025 and held it in 2 quarters.
Central Trust Company's Astera Labs position peaked at $676 in Q4 2025.
988 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.